The U.S. Influenza Market was valued at US$ 2.7 billion in 2021 and is expected to witness a CAGR of 16.2% over the forecast period 2022â€“2028 Influenza is an upper respiratory tract disease and is caused by the influenza virus. U.S. Influenza Market is mainly three types namely Influenza A, Influenza B, and Influenza C. Influenza is a communicable disease, spread through a flu cough, droplets from the infected people, sneeze or talks. The common symptoms occur in influenza patients are chills, cough, running nose, sore throat, body aches, headache, fatigue, some cases people may have vomiting and diarrhea. The complication of the disease may include ear infections, bacterial pneumonia, dehydration, sinus infections, and sometimes it leads to congestive heart failure, and asthma. Influenza commonly occurs in geriatric population and children with less than 5 years of age. Â The infection may be confirmed by testing the sputum, nose, or throat for the virus. A number of rapid tests are available however polymerase chain reaction that detects the virus's RNA is more accurate. Influenza vaccines are key revenue contributor for the growth of U.S. influenza market. The U.S. influenza market is in growing phase, several international players are actively involved in the development of vaccines and drugs to treat influenza. The launch of new products, technological innovations, and approvals from U.S. Food and Drug Administration (FDA) for various drugs might fuel the growth of U.S. influenza market. For instance, Squires used both egg and cell-based technologies to offer the broadcast portfolio of influenza vaccines in the U.S. for both trivalent and quadrivalent formulations. Similarly, transformative changes in other vaccine markets, due to the entrance of expensive and innovative vaccines such as Gardasil (Merck) and Bexsero (GSK) are projected to contribute growth of the U.S. influenza market. In May 2016, Seqirus received approval from U.S. Food and Drug Administration for Flucelvax Quadrivalent, that was the first U.S. licensed cell-based quadrivalent influenza vaccine indicated for people aged four years and older. In November 2016, GSK received approval from U.S. Food and Drug Administration for flulaval Quadrivalent to include use in children aged six months or older
Fastest Growing Market
The U.S. Influenza market is growing at a significant CAGR due to rise in newborn babies, an increase in geriatric population. Increase in vaccination awareness, favorable reimbursement scenario, and rising investment by companies in research and development activities are the major factors fuelling the growth of U.S. influenza market over the forecast period. The major market players have great pipeline products, initiatives by government bodies such as WHO and CDC to control and prevent influenza, technological advancements in diagnostic tests also fuel the growth of U.S. influenza market over the forecast period. However, limited production capacity, a high level of required investment, and stringent regulatory policies for new product approvals might hamper the growth of U.S. Influenza market. Due to limitations in current technologies, the lengthy production times (approximately seven months), increase in prices of influenza diagnostic kits and reagents also hinder the U.S. Influenza market.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.